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Abstract 
 
Objective 
To investigate the association between C-reactive protein (CRP) and the risk of 
developing diabetes in Aboriginal Australians. 
 
Research design and methods 
High sensitivity CRP levels were measured in 620 Aboriginal participants aged 
20–74 years free from diabetes at baseline in a remote community in the Northern 
Territory of Australia. Participants were followed for a median of 11 years to 
identify newly diagnosed cases of diabetes. Cox proportional hazards models were 
used to assess the relationship of CRP levels with the risk of developing diabetes 
over the follow-up period. 
 
Results 
A total of 109 participants were newly diagnosed with diabetes. Incident rates 
were 10.8, 16.6 and 28.8 per 1000 person-years for people in the lower, middle 
and upper tertile groups of baseline CRP levels, respectively. After adjusting for 
age, sex, BMI, baseline glucose regulation status, total cholesterol, urine albumin 
to creatinine ratio, systolic blood pressure, smoking and alcohol drinking, the 
association between diabetes and CRP remained significant, with a hazard ratio of 
1.23 (95% confidence interval (CI) 1.05, 1.45) corresponding to a doubling in CRP 
values. Similarly, the adjusted hazard ratio for development of diabetes in people 
in the upper tertile versus the bottom two tertiles of CRP was 1.75 (95% CI 1.19, 
2.56). 
 
Conclusions 
CRP is independently associated with the development of diabetes in Aboriginal 
people. Our findings support a role of inflammation in the etiology of diabetes in 
the high risk population of Aboriginal Australians. 
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There has been an increasing interest in the involvement of low grade inflammation in the 
pathogenesis of type 2 diabetes [1]. C-reactive protein (CRP) is an inflammatory marker produced 
and released by the liver under the stimulation of cytokines such as tumor necrosis factor-a and 
interleukins 1 and 6. It might affect the process of the atherothrombosis [2] and [3]. It has emerged as 
a powerful risk marker for cardiovascular disease [4], [5] and [6]. Inflammation has also been 
postulated to play a role in the pathogenesis of type 2 diabetes. Recent prospective studies have 
suggested that an elevated level of CRP is associated with an increased risk of developing type 2 
diabetes [7], [8], [9] and [10]. Some of the risk may be mediated through obesity and factors related 
to insulin resistance [10]. 
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Aboriginal Australians have a higher prevalence of diabetes than the general Australian population 
[11]. The causes of such a racial discrepancy in the prevalence of diabetes are still not clear. The 
distributions of CRP values vary significantly among race/ethnic groups [3] and [12]. The CRP level 
in Aboriginal population is much higher than that reported in other populations [13]. However, there 
is little information on inflammatory markers in high risk populations. There are no prospective 
cohort data from Aboriginal Australians evaluating the relationship between CRP and the 
development of type 2 diabetes. It is not known if inflammatory markers such as CRP can be useful 
for early detection of risk for diabetes in this high risk population. Therefore, we evaluated whether 
baseline CRP levels might independently predict future risk of diabetes among Aboriginal people, 
using prospective cohort data with a median of 11 years of follow-up. 
 
1. Research design and methods 
1.1. Study population 
 
From 1992 to 1995, a community-wide chronic disease screening program was conducted in a remote 
island community in the Northern Territory of Australia [14]. The program surveyed 897 participants 
aged 20–74 years, representing 83% of the total 1082 eligible adults in the community. Among them, 
136 participants had clinically manifested diabetes before the survey or were diagnosed with 
undetected diabetes at the baseline examination according to World Health Organisation (WHO) 1999 
criteria based on fasting and 2 h post load plasma glucose levels [15]. Seven hundred and sixty one 
(761) participants free from diabetes at baseline were followed for up to 13 years with a median of 11 
years. Serum samples were collected at baseline and stored at -70 °C until CRP testing. We further 
excluded 141 participants due to either insufficient quantity of the stored serum sample or no blood 
sample taken at baseline. The stored serum samples of 620 participants were retrieved for high 
sensitivity CRP testing in 2005. This project was approved by the Ethical Review Committee of the 
University of Queensland, the Human Research Ethics Committee of the Northern Territory 
Department of Health and Community Services and Menzies School of Health Research and the 
community health board. 
 
1.2. Ascertainment of diabetes 
Development of diabetes during the follow-up period was determined through hospital and clinic 
records according to International Classification of Disease (ICD) codes: 250 in ICD-9 CM and E11 in 
ICD-10-AM. Only first diabetic incidents were included in the analysis. All participants were 
followed up to 30 April 2005. For those who were diagnosed as having diabetes during the follow-up 
period, their follow-up time was from the time of the initial screening visit when the serum sample 
was taken to the time of the first diagnosed diabetes. Those who had not reached an endpoint were 
considered “censored” on 30 April 2005. Participants who were free from diabetes and had died 
before the end of follow-up were censored at the time of death. 
 
1.3. CRP measurements 
All 620 baseline samples were analyzed for high sensitivity CRP using the immunoturbidimetric 
CRP assay on a Hitachi 917 analyzer (Roche Diagnostics Australia) with a detection limit of 0.03 
mg/L. The assay's analytical range was from 0.1 to 20 mg/L. Samples with values greater than 20 
mg/L were measured using diluted samples. The imprecision of the assay is less than 5%. The 
laboratory staff members who performed CRP analysis were not aware of the diabetes status of the 
study participants. 
 
1.4. Measurements of baseline characteristics 
During the baseline visit, a fasting venous blood sample was drawn for plasma glucose, serum total 
cholesterol and triglyceride measurements. For some participants who were free from diabetes at 
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baseline, plasma glucose levels were also measured 2 h after a 75 g oral glucose challenge. An 
individual with a fasting plasma glucose concentration of 5.6– 
6.9 mmol/L was considered as having impaired fasting glucose (IFG) while those with a 2 h or 
random plasma glucose level of 7.8–11.0 mmol/L as impaired glucose tolerance (IGT). Impaired 
glucose regulation was defined as the presence of either IFG or IGT or both. Body weight, body 
height, waist circumference and blood pressures were measured at baseline. Body mass index 
(BMI) was calculated as weight in kilograms divided by height in meters squared. Overweight was 
defined as BMI 25–29.9 kg/m2 and obesity as BMI 30 kg/m2 or greater. Self reported past and 
current cigarette smoking and alcohol drinking were recorded at baseline. All measurements of 
baseline characteristics had been obtained before incident diabetes was diagnosed. 
 
1.5. Statistical analysis 
Participants who were free from diabetes at baseline were divided into three groups according to age 
and sex specific CRP tertiles. We compared the baseline characteristics among the three groups using 
a Chi square test for dichotomous variables. To assess the association between CRP and the incidence 
of diagnosed diabetes, we calculated hazard ratios using Cox proportional hazards regression. We 
calculated crude hazard ratios and the hazard ratios stratified by each of BMI, waist circumference, 
impaired glucose regulation status and gender. To further assess the independent contribution of serum 
CRP at baseline to the risk of diabetes, hazard ratios and their 95% confidence intervals (CI) were 
estimated using the Cox proportional hazards model adjusting for potential confounding factors such 
as age, sex, an impaired glucose status, BMI, urine albumin to creatinine ratio and serum cholesterol. 
In addition to categorizing CRP into tertiles, we also used CRP as a continuous variable to examine 
the association between CRP and the risk of diabetes. Since the distribution of CRP values was highly 
skewed, the logarithmic transformed values were used. For the ease of interpretation of the hazard 
ratios, we used a base 2 logarithmic transformation. The hazard ratio of the transformed value was 
interpreted as the increase in diabetes risk corresponding to a doubling of the CRP values. All analyses 
were performed using Stata 9.0 [16]. 
 
2. Results 
2.1. Baseline characteristics 
 
The CRP values ranged from 0.1 to 220.2 mg/L. Table 1 shows the baseline characteristics of study 
participants in different baseline CRP tertiles. The three groups had similar distributions of age, sex, 
total cholesterol, high density lipoprotein cholesterol, blood pressures and alcohol drinking status. 
Those in the higher CRP tertile groups had higher BMI and waist circumference values and a higher 
prevalence of impaired glucose regulation. People in the middle tertile group were more likely to be 
smokers. 
 
2.2. Development of diabetes and baseline CRP levels 
During a total of 6010 person-years of follow-up, 109 study participants developed diabetes. The 
probability of developing diagnosed diabetes during the follow-up period for all study participants 
increased with the increasing CRP tertiles, as shown in Fig. 1. The same trend was observed among 
different BMI groups (Fig. 2). Table 2 shows the incidence rates of diagnosed diabetes according to 
baseline CRP levels. The incidence rate of diabetes increased with an increasing level of CRP. The 
crude incidence rates were 10.8, 16.6 and 28.5 per 1000 person-years for lower, middle and upper 
tertile groups, respectively. Stratified by each of body mass index, waist circumference, impaired 
glucose regulation and sex, the trend of an increased incidence of diabetes in the top tertile group 
remained in each stratum. 
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TABLE 1. Baseline characteristics of Aboriginal participants stratified according to baseline C-reactive 
protein (CRP) concentrations 
 
 CRP tertile P-value 
 Lower Middle Upper  
No. of participants 211 207 202  
Age (years)a 31.4 (11.8) 32.0 (11.3) 31.9 (11.3) 0.86 
Body mass index (kg/m2)a 21.1 (3.6) 23.3 (5.3) 24.3 (5.5) <0.001 
Waist circ. (cm)a 80.8 (10.3) 87.1 (13.2) 90.6 (14.2) <0.001 
Systolic pressure (mmHg)a 119.7 (18.7) 119.6 (16.9) 120.7 (18.0) 0.77 
Diastolic pressure (mmHg)a 73.0 (12.8) 72.9 (14.0) 74.2 (13.0) 0.54 
Total cholesterol (mmol/L)a 4.4 (0.9) 4.6 (1.2) 4.6 (1.1) 0.14 
Triglycerides (mmol/L)b 1.65 (1.53, 1.79) 1.68 (1.55, 1.82) 1.76 (1.63, 1.90) 0.52 
C-Reactive protein (mg/L)b 1.64 (1.49, 1.80) 4.83 (4.52, 5.15) 14.6 (13.3, 15.9) <0.001 
Male (%)c 113 (53.6) 109 (52.7) 108 (53.5) 0.98 
Impaired glucose regulation (%)c 15 (7.1) 31 (15.0) 36 (17.8) 0.004 
Smoking (%)c 155 (73.5) 165 (79.7) 134 (66.3) 0.01 
Drinking (%)c 130 (61.6) 120 (58.0) 118 (58.4) 0.71 
a Mean (standard deviation). 
b Geometric mean (95% CI). 
c Number (%). 
 
 
 
Fig. 1. Kaplan–Meier estimates of the cumulative distribution function for developing type 2 diabetes during the 
follow-up period in Aboriginal Australians. 
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Fig. 2. Incidence rate of type 2 diabetes according to BMI and CRP tertiles. 
 
TABLE 2. Incidence of diagnosed diabetes in Aboriginal people without diabetes at baseline according to 
baseline C-reactive protein (CRP) concentrations 
 
Stratum CRP tertile 
No. of diabetes 
cases 
No. of person-
years Rate
b HRa 95% CIa P-value 
All participants Lower 23 2135 10.8 1   
 Middle 34 2051 16.6 1.54 0.90, 2.61  
 Upper 52 1824 28.5 2.63 1.61, 4.30 <0.001 
Stratified by BMIa 
 BMI<25 Lower 18 1870 9.6 1   
 Middle 11 1344 8.2 0.85 0.40, 1.80  
 Upper 16 1187 13.5 1.39 0.71, 2.73 0.42 
 BMI 25+ Lower 5 265 18.9 1   
 Middle 23 707 32.5 1.68 0.64, 4.43  
 Upper 36 637 56.5 2.97 1.16, 7.57 0.014 
Stratified by waist circumference 
 (<80 cm, 
female; Lower 10 1558 6.4 1   
 <94 cm, male) Middle 7 1181 5.9 0.93 0.35, 2.45  
 Upper 9 937 9.6 1.51 0.61, 3.71 0.57 
 (80+ cm, Lower 13 578 22.5 1   
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Stratum CRP tertile 
No. of diabetes 
cases 
No. of person-
years Rate
b HRa 95% CIa P-value 
female; 
 90+ cm, male) Middle 27 870 31.0 1.36 0.70, 2.64  
 Upper 43 887 48.5 2.14 1.15, 3.99 0.024 
Stratified by glucose level 
 Normal glucose Lower 21 1982 10.6 1   
 Middle 20 1804 11.1 1.05 0.57, 1.94  
 Upper 34 1536 22.1 2.09 1.22, 3.61 0.01 
 IFT/IGTa Lower 2 153 13.1 1   
 Middle 14 247 56.6 4.19 0.95, 18.45  
 Upper 18 288 62.5 4.65 1.08, 20.05 0.036 
S 
 Female Lower 12 975 12.7 1   
 Middle 22 926 27.3 1.90 0.94, 3.85  
 Upper 36 784 43.0 3.69 1.92, 7.11 <0.001 
 Male Lower 11 1161 9.2 1   
 Middle 12 1125 10.9 1.14 0.50, 2.57  
 Upper 16 1040 15.4 1.62 0.75, 3.50 0.43 
a HR, hazard ratio; CI, confidence interval; BMI, body mass index; IFG, impaired fasting glucose; IGT, impaired 
glucose tolerance. 
b per 1000 person-years. 
The crude hazard ratios of diabetes were 1.54 (95% confidence interval: 0.90, 2.61) and 2.63 (95% CI: 
1.61, 4.30), respectively, for middle and upper tertiles in comparison with the lowest tertile. 
Stratified by each of BMI, waist circumference, impaired glucose regulation and gender, the upper 
tertile consistently had a higher risk than the lower tertile even though it did not reach statistical 
significance in some strata (Table 2). 
Table 3 shows the hazards ratio of diabetes adjusting for different sets of potential 
confounding factors in Cox proportional hazards models. After adjustment for age and sex, the CRP 
level as a continuous variable was significantly associated with the risk of diabetes. The hazard ratio 
for diabetes associated with a doubling of CRP value was 1.34 (95% CI: 1.17, 1.54). Further 
adjustment for BMI attenuated the observed hazard ratio to 1.24 (95% CI: 1.06, 1.44) but remained 
statistically significant. Adding variables such as baseline glucose level, total cholesterol, urine 
albumin to creatinine ratio, blood pressure, smoking and alcohol drinking did not alter the hazard 
ratio estimate (Table 3). No significant interactions between CRP and BMI, impaired glucose 
regulation and sex were observed. 
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TABLE 3. Adjusted hazard ratios of type 2 diabetes according to baseline CRP concentrations in Aboriginal 
Australians 
 HR 95% CI P-value (likelihood ratio test)
CRP as continuous variable 
 Adjusted 1a 1.34 1.17, 1.54 <0.001 
 Adjusted 2b 1.24 1.06, 1.44 0.006 
 Adjusted 3c 1.24 1.07, 1.45 0.005 
 Adjusted 4d 1.23 1.05, 1.45 0.01 
CRP upper tertile versus the bottom two tertiles 
 Adjusted 1a 2.11 1.45, 3.07 <0.001 
 Adjusted 2b 1.68 1.14, 2.46 0.008 
 Adjusted 3c 1.69 1.15, 2.47 0.007 
 Adjusted 4d 1.75 1.19, 2.56 0.004 
 
a Adjusted for age, sex. 
b Adjusted for age, sex and BMI. 
c Adjusted for age, sex, BMI, and baseline glucose regulation status. 
d Adjusted for age, sex, BMI, baseline glucose regulation status, urine albumin to creatinine ratio, total 
cholesterol, systolic blood pressure, smoking and alcohol drinking. 
 
Due to relatively small numbers of diabetes cases in the lower and middle tertiles of CRP, we 
combined the two bottom tertile groups as the reference group to estimate adjusted hazard ratios for 
upper tertile. The hazard ratio adjusting for age and sex was 2.11 (95% CI: 1.45, 3.07). Similar to 
using CRP as a continuous variable, the hazard ratio was attenuated after adjusting for BMI. The 
hazard ratio adjusting for age, sex, BMI, impaired glucose regulation, total cholesterol, urine albumin 
to creatinine ratio, systolic blood pressure, smoking and alcohol drinking was 1.75 (95% CI: 1.19, 
2.56). 
One hundred and twenty eight participants developed cardiovascular disease or renal failure 
during the follow-up period. They are more likely to be diagnosed with diabetes in the follow up 
period than those without those conditions. Therefore, we recalculated adjusted hazards ratio 
excluding those who had cardiovascular disease or renal failure. Although the sample size was 
reduced substantially, the association between CRP and incident diabetes remained statistically 
significant for the doubling in CRP values, with a fully adjusted hazard ratio of 1.32 (95% CI: 1.08, 
1.63). The adjusted hazard ratio for the upper tertile was 1.70 (95% CI: 0.99, 2.94). 
 
3. Discussions 
In this prospective cohort study in a high risk population of Aboriginal Australians, we observed a 
significant positive association between elevated CRP levels and incident diabetes. Higher CRP levels 
were strongly associated with BMI—an indicator of obesity, which is an important risk factor for the 
disease. Adjustment for BMI weakened the association between CRP and the risk of developing 
diabetes. However, the association remained statistically significant even after adjusting for age, sex, 
BMI, impaired glucose regulation, systolic blood pressure, total cholesterol, urine albumin to 
creatinine ratio, smoking and drinking. We found a 75% increased risk for those with upper tertile 
CRP values relative to the bottom two tertiles. 
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The association between inflammatory markers and incident diabetes has been examined in a 
few prospective studies in other populations [7], [8], [9], [10], [17], [18] and [19]. A study in Mexico 
City showed that the association was strong and significant in women but not in men [17]. An 
independent association was observed in women aged 45-year or older in the United States [7], in 
middle-aged men in Eastern Finland [10] and in Japanese American men and women [9]. In a matched 
case-control study in a high risk population of Pima Indians, no association between CRP and diabetes 
was found [20], possibly due to the lack of power due to the small sample size. 
 Adjusting for BMI and other factors attenuated, but did not eliminate, the association between 
CRP and incident diabetes in this study. This phenomenon has also been consistently documented in 
other populations [7], [8] and [10]. It was expected, due to the strong association between CRP and 
BMI and a strong association between BMI and risk of developing diabetes. Two possible 
explanations have been suggested. First, inflammation could be one mechanism by which known risk 
factors, such as obesity and factors related to insulin resistance, promote the development of diabetes 
[8]. Second, some of the risk of CRP could be mediated through those known risk factors [10]. 
 Although the estimates of the hazards ratios varied among different strata, no significant 
interactions were observed. It should be noted that the small size in some strata might have hampered 
our ability to find significant interactions. Most previous prospective studies of Caucasian populations 
examined either men [8] and [10] or women alone [7]. Studies in Mexicans [17] and Japanese 
Americans [9] examined and compared the associations between CRP and incident diabetes in both 
sexes. In both studies the association tended to be higher in women than in men. Hak et al found a 
stronger association of inflammatory markers with insulin concentrations in elderly women than in 
men [21]. Aboriginal women with diabetes experienced a higher risk of coronary heart disease than 
Aboriginal men [22]. Whether CRP plays a more important role in females and in overweight and 
obese individuals in Aboriginal Australians remains to be further examined with large study samples. 
 The study population had a higher prevalence of diabetes than the general Australian 
population [11]. In addition, they also have higher CRP levels than other populations [13]. The strong 
and independent association between CRP and the risk of developing diabetes suggests that 
inflammation in may be partly responsible for the increased risk of diabetes in this population. 
Therefore, controlling inflammation may have important implications in prevention of diabetes and its 
complications in this population. 
 Our findings add to the growing body of evidence implicating low-grade inflammation as an 
independent predictor of diabetes. However, the exact effect of inflammation on glucose metabolism 
in humans is still unclear. There are several possible mechanisms through which inflammation might 
impair insulin action [23]. It has been postulated that type 2 diabetes may be a manifestation of 
activated innate immunity [1]. Inflammatory cytokines can attenuate insulin-induced suppression of 
hepatic glucose production, decrease lipoprotein lipase activity and stimulate lipolysis in adipose 
tissue [24]. Several drugs with anti-inflammatory properties lower both acute-phase reactants like CRP 
and glycemia [1] and [25]. The West of Scotland Coronary Prevention Study showed that pravastatin 
therapy resulted in a 30% reduction in the risk of developing type 2 diabetes. The anti-inflammatory 
effects of pravastatin might be partly accountable for the reduction [26]. 
 This study has several strengths. Over 80% adults in the community were included in the 
cohort with a complete follow-up. The participants with both clinically diagnosed and survey 
diagnosed diabetes according to plasma glucose values at baseline were excluded. The baseline 
measurements of exposure CRP levels were determined by the laboratory persons who were not aware 
of the future diabetes status. The diagnosis of diabetes during the follow-up period was not influenced 
by the baseline CRP levels since the information was not available to the clinicians who made the 
diagnosis. However, a few limits of this study should be addressed. First, the onset of type 2 diabetes 
is usually insidious. The diabetes cases in this study were identified through hospital and clinical 
records, and some participants with diabetes might not have been identified. This could have biased 
our results toward the null. Second, misclassification of exposure cannot be excluded since only one 
blood sample was taken for each participant for CRP testing. Acute infections lead to temporarily 
increased CRP levels, which do not represent the true basal CRP value. Even the baseline CRP value 
measured when the participant was free from acute infections might still not represent the usual CRP 
level during the long-term follow-up period due to within-person variability. This bias, referred to as 
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regression dilution bias [27] and [28], could have also biased our effect estimates toward the null. 
Third, due to a relative small sample size, especially a small number of diabetes cases, we combined 
the two bottom tertile groups as the reference for calculating hazard ratios. Since the reference group 
might have contained individuals with an elevated CRP concentration as well as an increased risk of 
diabetes, the hazard ratios that were reported in this study represented conservative estimates of risk of 
CRP for diabetes. Fourth, some lifestyle factors were not included in this study. Guest and O’Dea 
reported that Aboriginal people consumed more salt and were more likely to eat takeaway food as a 
meal than non-Aboriginal Australians [29]. It is not clear to what degree the observed association 
reflects the effects of diet and lifestyle differences. 
 In conclusion, we show that a positive association between levels of CRP and incident 
diabetes, which supports a role of inflammation in the etiology of diabetes in the high risk population 
of Aboriginal Australians. The association was independent of established risk factor for diabetes. 
Therefore, inflammatory markers, like CRP, can be useful for early detection of high risk individuals. 
 
Acknowledgments 
This work was funded by the National Health and Medical Research Council (NHMRC) of Australia (301024 
and 320860). We especially thank the Tiwi people who participated in this study; the Tiwi Land Council and 
the local clinics for their help and support; David Ung for assistance in hospital data collection. The baseline 
data were collected by the renal research team at the Menzies School of Health Research, Darwin. Mark 
Shephard from the Community Point-of-Care Services unit at the Flinders University Rural Clinical School is 
gratefully acknowledged for his contribution to CRP testing. 
 
References 
[1] J.C. Pickup, Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes, Diabetes Care 27 
(2004), pp. 813–823. 
[2] V. Pasceri, J.T. Willerson and E.T. Yeh, Direct proinflammatory effect of C-reactive protein on human endothelial 
cells, Circulation 102 (2000), pp. 2165–2168. 
[3] S.H. Li, P.E. Szmitko, R.D. Weisel, C.H. Wang, P.W. Fedak and R.K. Li et al., C-reactive protein upregulates 
complement-inhibitory factors in endothelial cells, Circulation 109 (2004), pp. 833–836. 
[4] P.M. Ridker, M. Cushman, M.J. Stampfer, R.P. Tracy and C.H. Hennekens, Inflammation, aspirin, and the risk of 
cardiovascular disease in apparently healthy men, N. Engl. J. Med. 336 (1997), pp. 973–979. 
[5] E.T. Yeh and J.T. Willerson, Coming of age of C-reactive protein: using inflammation markers in cardiology, 
Circulation 107 (2003), pp. 370–371. 
[6] P.M. Ridker, Clinical application of C-reactive protein for cardiovascular disease detection and prevention, 
Circulation 107 (2003), pp. 363–369. 
[7] A.D. Pradhan, J.E. Manson, N. Rifai, J.E. Buring and P.M. Ridker, C-reactive protein, interleukin 6, and risk of 
developing type 2 diabetes mellitus, J. Am. Med. Assoc. 286 (2001), pp. 327–334. 
[8] B. Thorand, H. Lowel, A. Schneider, H. Kolb, C. Meisinger and M. Frohlich et al., C-reactive protein as a predictor 
for incident diabetes mellitus among middle-aged men: results from the MONICA Augsburg cohort study, 1984–1998, 
Arch. Intern. Med. 163 (2003), pp. 93–99. 
[9] S. Nakanishi, K. Yamane, N. Kamei, M. Okubo and N. Kohno, Elevated C-reactive protein is a risk factor for the 
development of type 2 diabetes in Japanese Americans, Diabetes Care 26 (2003), pp. 2754–2757. 
[10] D.E. Laaksonen, L. Niskanen, K. Nyyssonen, K. Punnonen, T.P. Tuomainen and V.P. Valkonen et al., C-reactive 
protein and the development of the metabolic syndrome and diabetes in middle-aged men, Diabetologia 47 (2004), pp. 
1403–1410. 
[11] Z. Wang and W.E. Hoy, Hypertension, dyslipidemia, body mass index, diabetes and smoking status in Aboriginal 
Australians in a remote community, Ethn. Dis. 13 (2003), pp. 324–330. 
[12] M.A. Albert, R.J. Glynn, J. Buring and P.M. Ridker, C-reactive protein levels among women of various ethnic groups 
living in the United States (from the Women's Health Study), Am. J. Cardiol. 93 (2004), pp. 1238–1242. 
[13] Z. Wang and W.E. Hoy, Population distribution of high sensitivity C-reactive protein values in Aboriginal 
Australians: a comparison with other populations, Clin. Biochem. 39 (2006), pp. 277–281. 
[14] W.E. Hoy, P.R. Baker, A.M. Kelly and Z. Wang, Reducing premature death and renal failure in Australian 
Aboriginals. A community-based cardiovascular and renal protective program, Med. J. Aust. 172 (2000), pp. 473–478. 
[15] World Health Organization: definition, diagnosis and classification of diabetes mellitus and its complications. Part 1. 
Diagnosis and classification of diabetes melitus. Geneva, Department of Noncommunicable disease Surveillance, WHO, 
1999. 
[16] StataCorp: Stata Statistical Software: Release 9.0. College Station, TX, StataCorp LP, 2005. 
Diabetes Research and Clinical Practice (in press)                         doi:10.1016/j.diabres.2006.07.018 
[17] T.S. Han, N. Sattar, K. Williams, C. Gonzalez-Villalpando, M.E. Lean and S.M. Haffner, Prospective study of C-
reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study, 
Diabetes Care 25 (2002), pp. 2016–2021. 
[18] D.J. Freeman, J. Norrie, M.J. Caslake, A. Gaw, I. Ford and G.D. Lowe et al., C-reactive protein is an independent 
predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study, Diabetes 51 (2002), 
pp. 1596–1600. 
[19] M.I. Schmidt, B.B. Duncan, A.R. Sharrett, G. Lindberg, P.J. Savage and S. Offenbacher et al., Markers of 
inflammation and prediction of diabetes mellitus in adults (Atherosclerosis risk in Communities study): a cohort study, 
Lancet 353 (1999), pp. 1649–1652. 
[20] J. Krakoff, T. Funahashi, C.D. Stehouwer, C.G. Schalkwijk, S. Tanaka and Y. Matsuzawa et al., Inflammatory 
markers, adiponectin, and risk of type 2 diabetes in the Pima Indian, Diabetes Care 26 (2003), pp. 1745–1751. 
[21] A.E. Hak, H.A. Pols, C.D. Stehouwer, J. Meijer, A.J. Kiliaan and A. Hofman et al., Markers of inflammation and 
cellular adhesion molecules in relation to insulin resistance in nondiabetic elderly: the Rotterdam study, J. Clin. Endocrinol. 
Metab. 86 (2001), pp. 4398– 4405. 
[22] Z. Wang and W.E. Hoy, Association between diabetes and coronary heart disease in Aboriginal people: are women 
disadvantaged?, Med. J. Aust. 180 (2004), pp. 508–511. 
[23] R. Nesto, C-reactive protein, its role in inflammation, Type 2 diabetes and cardiovascular disease, and the effects of 
insulin-sensitizing treatment with thiazolidinediones, Diabet. Med. 21 (2004), pp. 810–817. 
[24] C. Grunfeld and K.R. Feingold, Regulation of lipid metabolism by cytokines during host defense, Nutrition 12 
(1996), pp. S24–S26. 
[25] P.M. Ridker, C.P. Cannon, D. Morrow, N. Rifai, L.M. Rose and C.H. McCabe et al., C-reactive protein levels and 
outcomes after statin therapy, N. Engl. J. Med. 352 (2005), pp. 20– 28. 
[26] D.J. Freeman, J. Norrie, N. Sattar, R.D. Neely, S.M. Cobbe and I. Ford et al., Pravastatin and the development of 
diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study, Circulation 
103 (2001), pp. 357–362. 
[27] S. MacMahon, R. Peto, J. Cutler, R. Collins, P. Sorlie and J. Neaton et al., Blood pressure, stroke, and coronary heart 
disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution 
bias, Lancet 335 (1990), pp. 765–774. 
[28] M.W. Knuiman, M.L. Divitini, J.S. Buzas and P.E. Fitzgerald, Adjustment for regression dilution in epidemiological 
regression analyses, Ann. Epidemiol. 8 (1998), pp. 56–63. 
[29] C.S. Guest and K. O’Dea, Food habits in Aborigines and persons of European descent of south eastern Australia, 
Aust. J. Public Health 17 (1993), pp. 321–324. 
 
